For man» years, neurosurgeons and otolaryngologic Sllrgeolls have used the fib rin glue product Tisseel to repair skull-base spinal fluid leaks and to help secure repairsfollowing anterior cranial-base surgery, Despite thelVidespread use, the potential fo cal cerebral toxicity of thisjib rin glue has never been investigated. We studied the safety of TisseeI appli ed directly to neural tissue (brain parenchyma , cervical cord, and C3-C6 spinal roots) of6 11l0llkeys (Mac aca nemestrin a) to determin e ij any underiying biochemical inju ry would occur. Another 3 nnimals that serve d as controls received saline rather thanTissee I. WeJoUlldthat median nerve electroencephalographic tracings and sotnatosensory evoked potentials iil the experimental and control animals were ideniieal. likewise. cerebrospinal fluid indicators of neuronal or brain injury, inflammatory responses, and infe ction were negativeiilbotli gro ups. Finally, there were Il a significant differellces between the two groups with respeet to edema vohl/lles and apparent diffusio n coefficient values. We colldllde that Tisseel does not induce an apparent inflammatory response or abnormal neurophysiologic or histologic response within 5 days oJ its appl ication when it is applied directly to the brain parenchyma or anta the cervical spinal cord.
Introduction
The demonstrated effec tiveness and safety of fibrin glue (thro mbin-containing mate rial) in sealing duralleaks has led to its widespread use in clinical neuro surgi cal proc edure s."!' Tisseel (a fibrin sealant) was approved by the United States Food and Dru g Administration in 1988, 12 despite the fact that studies in animaIs ex posed to thrornbin revealed that thrombin causes brain edema ," :" neuronal injury," apoptosis," and seizures." In addition, inhibition of factor V and bovin e thrombin, which can develop followin g thrombin exposure, reportedly induc ed coag ulopathy and inflammatory reactions." :" Although these studies were not conducted with Ti sseel, they raised the specter that Tisseel might cause similar adverse effec ts in view of its hum an thrombin constituent.l-"
It is important that Ti sseel' s effects be studied in nonhuman primates becau se their blood groupS23.24 and coagulation cascadev -" are similar to tho se of man . Use of the nonhuman prim ate-sized brain also allows for higher resoluti on on magnetic resonance imaging (MRI). In this article, we describe our study of the effect s of Tisseel applied directly to the brain parenchyma, the cer vical cord , and spinaI nerves of 6 monkeys.
M ater ials and methods A nimals. Following a protocol appro ved by the Institutional Animal Care and Use Committee at our institution (pro tocol #00 10896) , we quarantined 9 research-naive, pigtail monkeys (Macaca nemestrina ) of both sexes for 30 days. The animaI s weighed between 5 and 7 kg. They were free of tubercul osis, hepatitis, and simian immunovirus and retroviru s. The monkeys were maintained in a tempe rature-controlled environment (72 to 75°F) with a 12-hour light/12-hour dark cycl e. They wer e fasted overnight prior to the study, but they had free aecess to wate r. Six monkeys were includ ed in the Tisseel group, and the remaining 3 served as cont roIs.
ENT-Ear, Nose & Throat Journal· April 2004 In c1iniccl triais, cammonly reported adverse events with RHINOCORT AQUA versus vehicle placebo were epistax is (8% vs 5%), pharyng itis (4% vs 3%), bronchospasm (2% vs 1%), coughing (2% vs < 1%), and nasal irritation (2% vs < 1%). The overall incidenee of adve rse events with RHINOCORT AQUA was similar to that observed with vehicle placebo. A similar adverse eventprolilewas observe d inthe subgroup 01pediatrie patients 6 to 12 years ofage. Two to threepe rcent (2-3%) 01patien tsincl inieal trialsdiseontinued beeause ofadverseevents. Systemieeort ieosteroid side effeets were not reported during eontrolled elinieal studies with RHINOCORTAOUA Nasal Spray. Il re eommendeddoses areexceeded,however, or if individual s are partieularly sensitive, sympt oms 01 hypereortieism , ie, Cushing'sSyndrome, eould oeeur. Rare adverse events reported from post-marketing experience mclude: nasal septum perforation, pharynx disorders (throat irrilation, throat pain. swollen throat, burning throat, and itehy Ihroat), angloedema, anosmia, and palpifat ions. Cases ofgrowth suppression have been rep orted forintranasal eortieosteroidsineludingRHINOCORTAOUA NasalSpray (seePRECAUTl ONS, Pediatrie Use). DOSAGE AND ADMINISTRATION Thereeommended starting dosefor adults and ehildren 6yearsof age andolderis64 meg per dayadministered as one spray per nostril ofRH INOCORTAOUA Nasal Spray32meg onee daily, Themaximum reeommended doselor adults(12 yearsofage and 01der) is256 meg perday admi ni ste red as four spraysper nostril onee daily of RHI NOCORT AOUA Nasal Spray 32 mcg and the maximum reeommended doseforpediatrie patients (<12 years01 age) is128meg per dayadministered as 11' 10 spraysper nostril onee daily of RHI NOCORT AOUANasal Spray 32 meg (see HOW SUPPUED) IndividuelizeHen el Desege: It is always desirabletotitratean indi vidualpatienttothe minimum effeetive dosetoredueeIhepossibility of side effeets . HOW SUPPLlED RHINOCORT AOUA Nasal Spray 32 meg is available in a green eoated glass bottle with a metered-dose pump sprayand a green protecti on eap. RHINOCORT AO UA Nasal Spray 32 meg provides 120 met ered sprays alter ini fial priming ; netfill weight 8.6g. TheRHINOCORT AOUA Nasal Spray 32 meg bottle has been lilled wi th an excess to aeeommodate the priming aetivity. The bottle should be dlsearded aher 120 sprays following init ial priming, sinee the amount of budesonide delivered per spray therealter may be substantiallylessthanIhe labeied dose. Eaeh spray delivers32 meg ofbudesonide tothe patient. Inrat s,budesonide eaused adeerease inprenatal viabi lityandviabllJty of thepups at birth and dur ing laetation, along wi thadeerease in matemal body-weight gain, atsubcutaneous doses of 20 meglkg and above (less thanthe maximum reeommended dailyintranasal dose inadult sonamcg/m 2 baSIS). Nosuch e!feets were noted at 5 meglkg (Iess than the maximum reeommended daily intranasal dose in aduits on a meg/m 1 basls). Pregnancy: T eralogenic Elteets: Pr egnaney Category C: Budesonide wa steratogenieand emb ryoeidal in rabbits and rats. Budesonide produeed let al loss. deere ased pup weights, and skelet al abnorrnalities at sube utaneous doses 01 25 meg/kg in rabbits and 500 meg/kg in rats (approximately 2 and 16times the maximumreeommended dailyintranasal doseinadultsonameg/m 1 basis).ln anotherstudyinrats, no teratogenie or em bryoeidal effeets were seen at inhalation doses up to 250 megf,g (approximately 8 times the maximumreeommended daily intranasal dose inadults onameg/m 2 basis). Thereareno adequate and welleontrolled studies in pregnant wornen, RHINOCORTAOUA Nasal Spray should be used du ring pregnaney only il the potential bene/it justilies the potentialrisk to the tetus. Experiencewithoral eortieosteroidssinee their introducti on in pharmaeol ogie, as opposed to physiologie, doses suggests that rodents are more prone to teratogenie effeetsfrom eortieosteroids than humans. Inaddition, beeause there isanatural inere aseincortieosteroidproduetionduring pregnaney, most women will requirealower exogenouseort ieosteroiddoseand many willnot need eortieosteroid treatment during pregnaney. Nont er atogenieElteets: Hypoadrenalism may oeeur inintants born 01 mothers reeeiving eortieosteroids du ring pregnaney. Suchintants should be earefully observed. Nursing Mo!hers: It isnot knownwhether budesonide isexereted in huma n milk. Beeauseother eortieosteroidsareexereted inhuman milk, eaution shouldbe exereised when RHINOCORT AOUA Nasal Spray isadministered tonu rsing women.Pediatric Use: Safety and effeetiveness inpediatricpat ientsbelow6years of age have not been established . Controlled el inieal studies haveshown that intranasal eortieosteroid s may eause areduetioningrowth velocity inpediatriepatients.This effeethas been observed inthe absenee oflaboratoryevidenee of hypothal ami e-pituitary-adrenal(HPA)-axis suppression, suggesting thatgrowth velocity is amore sensitive indieator 01 systemie eortieosteroid exposure inpediatriepatients than some com monly used tests of HPA-axis funetion.Thelong-termeileets 01thisreduetioningrowth velocity associated\' llthintranasal eortieosteroids, ineluding the impaet onfinal adult height, areunknown . The potentialfor"eateh up" gro\'. 1h following diseontinuation of treatment~I i th intranasal eorti eosteroidshas not been adeq uately studieö . The growth of pediatrie patients reeeiving inlranasal corticosteroids, ineluding RH INOCORT AOUA Nasal Spray, shouId be monitored routinely (eg, via stadiometry), The potential qrowth eff eets 01 prol ong ed tre atme nt should be weighedagainst clinical benefits obtained and the availabilityofsateand eff eetivenoneortieosteroid treatment al ternatives. To minimizethe systemieelleets 01intranasalcorticosterolds, ineluding RH INOCORT AQUA Nasal Spray, eaeh patientshould betitrated to the lowest dose that elleetively controis his/her symptoms. Geria!rie Use:of the 2,461 patients in elinieal studies of RHINOCORT AOUA Nasal Spray, 5% were 60years 01age and over, No overalt differenees insalety or eNeetiveness were observed betwe en these subjeets and younger sUbjeets, exeept lor an adverse event reporting Irequeney 01 epistaxis which inereased wi th age. furtl 1ef, other reported elini eal experience has not identified any othe r dlfferenees in responses belween elderly andyounger patients, but greater sensitivity01some older individual seannotbe ruled out. ADVERSE REACTIONSTheincidenee ofcommon adverse reaetionsisbased upontwo US. and tlve non-U S. eontrolled elinieal trials in 1,526 patients [110 lemales and 239 males less than 18 years 01 age, and 635 lemales and 542 males 18years 01 age andolder] treat ed withRHINOCORTAOU ANasal Sprayat doses upto 400 meg onee daily for3-6 weeks. Thetablebelow deseribes adverse events oeeu rring atan incidenee of 2%or greate r and more common among RH INOCORT AOUA Nasal Sp ray-treale d patients than in plaeebo-treated patients in con troll ed el inieal trials. The overall incidenee 01 ad ve rse events was si milar between RHINOCORT AOUA and plaeebo For Int ranasal UseOnly.
BRIEF SUMMARY INDICATIONSAND USAGE RHINOCORTAOUA Nasal Spray isindieatedforthe management 01nasal symptoms ofseasonal or perennial allergie rhinitisin adults and ehildrensixyears01 age and older. CONTRAINDICATIONS Hypersensitivit y toany ofthe ing redients inthis prepa ration eontraindieates the use ot RHINOCORT AOUANasal Spray. WARNINGSThereplacement ofasystemieeortieosteroidwith atopieal eortieoste roidean be aeeompanied by signs of adrenalinsuffieieney, and in addition some palients mayexperience symptoms of eorti eosteroid withdrawal. eg, joint and/ or museular pain, lassitude, and depression. Patients previously treated for prolonged periods with syst emieeortieosteroids and transferred totopieal eortieosteroids shouldbe earefully monitored lor aeuteadrenal insuffieiencyin responseto stress. In thosepatients who haveasthma or otherel inieal eonditions requiring long-term systemieeortieosteroidtreatment.too rapidadeerease insystemieeortieosteroids mayeause asevereexaeerbationoftheirsympt oms. Patientswho are ondrugswhichsuppress the immune system ar emore suseeptibletoinfeetions than healthyindividuals. Chicken poxand measles, for example, ean have amore serious or even fatal eourse in non-immune ehildren or adults onimmunosuppressant doses ofeortieosteroids . Insuch ehildren or adults whohave not had thesediseases , partieular eare should betakento avoid exposure. How the dose, route, and durafion 01eortieosleroid administration affeets the risk 01 developing adisseminated infeetion isnot known. The eontribution of theunderlying disease and/or prioreortieosteroid treatmerit totherisk is also not known. Il exposedtochicken pox, prophylaxis withvarieellazoster immune gl obulin (VZIG) may be indieated. AOUA Nasal Spray should reeeivethe following information and instruetions. Patients who are on immunosuppressant doses of eortieosteroids should be wamedtoavoidexposure toehiekenpoxormeaslesand, il exposed ,toobtainmedical adviee. Patientsshould useRHINOCORTAOUA Nasal Sprayat regul arintervals sinee its elleetiveness dependsonitsregularuse (see DOSAGE AND ADM INISTRATIO Nintuli Preseribing Inl ormat ion). An improvement in nasal symptoms may be noled in patientswithin10 hoursof lirst using RHINOCORT AOUA Nasal Spray. This timeto onset is supported byan environmental exposure uni! study inseasonal allergie rhinitis patientswhieh demonstrated that RHINOCORTAOUA Nasal Spray ledto astatistieally signilieantimprovement in nasal symptoms eompared toplaeebo by 10 hours. Further support eomes from aelinieal study 01patients with perennial allergierhinitis whieh demonstrat ed astatistieally signilieant improvement innasal symptoms forboth RH INOCO RTAOUA Nasal Sprayand lor the aetlve eomparator (mometasone furoate) eompared to plaeebo by 8 hours. Onsetwas also assessedinthisstudy with peak nasal inspiratorytlow rate and this endpoint tail ed toshow effieacyfor ei ther aetive treatment.Ailhough stat ist ieally signifieant improvements innasal symploms eompared to plaeebo were noted wi thin 8-10hours in these studies , about one half to11' 10 thirds 01 the ul timat eelinieal improvementwith RHI NOCORT AOUANasal Spray oeeursover the first 1-2days, and maximum benefit may noi be aehieved unlil approxi mately 2 weeks aNer initiation oftreatment. Initial assessment forresponseshould be made during this timetrame and periodieally until the patient's symptoms are stabi lized. Thepatientshould take themedieation as di reeted and should not exeeed thepreseribeddosage .Thepatient should eontaet the physieian it symptoms donot improve alter two weeks , or if the eondition worsens. Patients who experience reeurrent episodes of epistaxis (nosebleeds) or nasal septum diseomfort while taking this medication shouldeontaet their physieian. Forproper use ofthisunit and toattainmaximumimprovement.the patient should readand 101101' 1 the aeeompanying patient instruetions earefull y. It is important to shake the bottle weil before eaeh use. The RHINOCORT AOUA Nasal Spray 32 meg bottlehas beenfilled withanexcess toaeeommodate the primingaetivity. The bottle should be disearded aNer 120 spraysfollowing init ial priming, sinee theamounl of budesonide del ivered per spray therealter may be subsl antially less than the labeled dose . Oo not transfer any remaining suspension toanother bottle . DrugInteraetions:The mainroute 01 metabolism of budesonide, as weil as other eortieosteroids, is viaeytoehrome P450 (CYP) isoenzyme3A4 (CYP3A4 ). Alt eroral admi nistration ofketoeonazole, apotent inhibitorof CYP3A4,the meanplasmaeoneentration ot orally admi ni steredbudesonide inereased by more than se ven -lold . Coneomilant administration01other known inhibitors ofCYP3A4 (eg, itraeonazole, elarithromyein, erythromyein, etc.) may inhibit the metabolism of, and inerease thesystem ieexposureto, budesonide (seeWARNI NGSand PRECAUTlONS, General) Care should be exerei sed when budesonide iseoadminis!ered wi th long-term ketoeonazole and othe r known CYP3A4 inhibitors. Omeprazole, an inhibitor ofCYP2C19 , didnot have effeets on thepharm aeokineties oferal budesonide, whileeimetidine, primarily an inhibitor of CYP1A2, eaused a slightdeerease in budesonide elearanee and eorresponding inereaseinItsoral bioavailabil ity. Cardnogenesi s, Mu!ag enesis, Impairmen! ofF e r~l i ty : In atwo-year study in Sprag ue-Dawley rats , budesonide eaused a statistieally signilieant inereaseinthe incidenee ofgliomas inthe male rats reeeiving an oral dose of 50 meg/kg (approximately twicethemaxim um reeommended dailyintranasaldoseinadults andehildren on ameg/m 2 basis). No tumorigenielt y was seen in male and female rats at respeetiveoral doses up to 25and 50 meg/kg (approximately equal 10 andtwo times the maximum reeommended daily intr anasal dose in adults and ehildren on a meg/m 2 basis, respeetively), Intwo additional two-year studies inmale Fischer and Sprague-Dawley rats, budesonide eaused nogliomas atan oraldose of 50 meg/kg (approximately twice the maximumreeommended daily intranasal dose in adults and ehil dren on a meg/m 2 basis). However,in male Sprague-Dawl ey rats, budesonide eaused astat istiealty signifieant inerease inthe incidenee ofhepatoeellular tumors at an eral dose 01 50meglkg (approximately 1I' liee themaximum reeommendeddailyintranasal doseinadults and ehildren on ameg/m 1 basis). The eoneurrent refereneeeortieosteroi ds(prednisoloneand triamei noloneaeetonide) inthesetwo studies showed similar fmd ings. Ina91-week studyinmiee, budesonideeausednotreatment-relatede arei nogeni ei~1 atoral doses up to200 meglkg(approxi mately3times themaximum reeommendeddailyintranasal doseinadults and ehildren on a meglm 2 basis). 8udesonide was not mUlagenie or elastogenie in six diilerent test systems: Ames were anesthetized with 10 mg/kg ofketamine and I mg of atropine intramuscularly . A peripheral intravenous cat heter was inserted percutaneously into the saphenous vein, and the monkeys were int ubated with a cuffed endotracheal tube. One gram of IV cefazolin was ad mi nistered as prophy laxis agai nst infecti on. T he monkeys were immobili zed with 0 .06 mg/ kg of IV pancuronium bromide and anes thetized with 0.6 to 1.0% isofl ura ne , 66 % ni trou s ox ide, and 33 % oxygen. Th ey were mec ha nie ally ventilated du ring surge ry. Usi ng an ase ptic technique, we insert ed a ce ntral ven ou s cath et er into the fe mo ra l ve in for dru g infu sion , and we pl aeed a fem oral arte ria l lin e to mon itor arterial blood pressure and to obtai n art eri al blood sa mples (0. 5 mi ) fo r pH and blood gas measurement.
Th e du ra was incised via a left fro nta l cranio to my 2 cm in diam eter. Cor ticect om y ( I c m in length and depth) was per form ed in the middl e fro nta l gyrus for direet s ubpial placeme nt of the T isseel into the brain pa renc hy ma. In the 6 experimenta l mon keys, the corticecto my was filled with T isseel glue (-1.0 mi ), the dura! defect was sealed wi th T isseel , an d the cranial defect was sea led with bon e wax . In each contro l mon key, the corticectomy was fi lled with sa line an d the eranial defec t w ith bo ne wax. Th e ga leo pe rios tea l fla ps we re s utu red in place, and the sealp was staple d elosed .
Laminect omies at C3 -C4 we re performe d on 7 mo nkeys-4 in the T isseel group and the 3 co ntro is. T isseel (2 mi ) was inject ed into the right lateral intra thecal space throu gh a 25-gauge intracath, which ex tende d the passage of Ti sseel down to the CG level. Th e du ral defeet was sea led with Ti sseel in the 4 experi me ntai animai s and left un sea led in the 3 controi s.
Electroencepltalography and somatosensory evok ed potentials. Median ner ve elee troenee pha lographic (E EG) tracin gs and so ma tosenso ry evoked potential s (SSEPs) were record ed prior to surg ica l interventi on und er ket am ine anes thesia, then co ntinuo us ly for the first 24 hou rs fo llowin g the applica tio n of Tisseel. Th e goal of mon itoring was to evaluate spi na l cord, eervical nerve root, and brain fu nction for ev idence of seizures. Du ring the 24 -hour mon itoring period, the isoflurane/ni tro us ox ide anes thesia was repl aced by anesthesia wit h 25 u g/kg/h r of IV fen ta ny l; if an anima l co uld not ma intai n a systolic arterial b lood pressure of less than 14 0 m m Hg under fe nta nyl, a 2.5 mg/hr bo lus of diazepam was ad ministered. At 3 and 5 days postop era tivel y, repeat EEG and SSE P recordin gs were obtained und er ketamine anesthes ia.
Four-ch annel bihe misphe ric EEG reeordin gs were obtain ed via subperios tea l needi e elee trodes . SSEP recordings were obtained via bil ater almedi an ner ve stim ulatio n per formed independ entl y on each limb . Sc alp elec tro des wer e plaeed at P4/Fz and P3/Fz (ae cording to a modified Volume 83, Number 4 intern at ion al I 0-20 system), and the subcortical electrode was placed at the mastoid and referenced to Fz. SSEPs were elicited by producin g suffieient intensity to evoke a co nsistent response at a stimulation freq ue ncy of 3.43 H z and a duration of 0 .2 msec. Band-pass filters were se t between 3 and 300 Hz wit h a gai n of 20 ,000 for eortieal recordings and bet ween 30 Hz and I kH z with a ga in of 50 ,000 for eervical reeordi ngs . A verages were co mp uted for 128 tri al s, and at least two averages we re co mputed fo r each limb. A verages for the co ntro is were obtaine d to verify the lac k of conta mina tio n by nonbiol ogieal no ise . EEG and SSEP data were rev iewed by a neurophysi ol ogist (J.B .) wh o had been blinded to ea ch primate' s treatment.
Twenty-four-hour monitaring and S-day observation.
In additio n to EEG and SSEP, we al so co ntinuous ly monitored blood pressur e, rect al temperature, cardiac rh ythm by electrocardiography, and ar teria l oxygenation by pulse oxi me try . To ensure norm al va lues, arteria l blood gases were measu red prior to ex tubat ion and pr ior to transport ofeac h subjeet to the reeovery roo m. Thr oughout the 5-day obse rva tion per iod , the mon keys were ke pt in cages w hile veter inary technicians provided 24-hour coverage to detee t behavioral sig ns of seizures . Im aging was obt ain ed by sag itta l T l-weight ed spinec ho and ax ial prot on-den sity and T 2-wei ght ed fas t-s pinec ho se que nces suppleme nted by axial flu id-attenuated inve rs ion recover y (FLA IR) EPl and T 2-weight ed gradient-echo se que nees. Altho ug h the ana to mie reso lutio n and soft-tiss ue co ntras t is exceptional at 3.0 Tesla, ac ute isc he mic cha nges ca nnot be de tec ted. Th erefore, we used DWI.
A DC mapping was ob tai ned by diffusion-we ig hte d, cerebrospina l fluid-(CSF) null ed, inversion-recovery EPl se quence optimized for isotropic di ffusion weighting. Di ffusion weighting was ineorporat ed in the sta ndard fas hio n by apply ing pul sed gradie nts (duration: 50 msec) sy mme tr ica lly abo ut the 180 0 refocu sin g pul se alter nativel y in the x, y, and z direc tio ns . ADC traee map s wer e ca leulated by voxel-w ise logar ithmic fi tting of the di rection almean signa l inten sity as a func tio n of b-v alu e.
Regi on almeasurem ent s o f di ffusion wei ghting, ADC, and ede ma vo lume ealeulated from the T 2-weighted im-247 KASSAM , NEMOTO , BALZER, RAO, WELCH, KUWA BARA, BOA DA, HOROWITZ age s were ana lyze d as a fune tio n of tim e after T isseel pl acement on the brain and spina l co rd to det ermine wheth er the Ti sseel had an y effe ets on tissu e fl uid cont ent, tissue permeab ilit y, and tissu e per fu sion adj ace nt to or rem ote fro m the locat ion s of its applica tio n, CSF analyses by enzy me-linked immunosorbent assay (EL/SA) . CSF samples (3 mi ) were obtained by lumbar pune ture before surgery and by ci ste rna magna puneture on pos teortieeetomy day 5 pr ior to perfusio n fixa tion of the brain. CSF sa mple s we re analyzed by ELISA for the fo llowi ng va lues:
• inter leukin-6 (l L-6) (R& D Systems; Mi nnea po lis), an indicator of the inflam matory resp on se to th e fibrin glue • neu ron-sp eei fie e no lase (NS E) (Sy n-X Ph arma ; Mississauga , Ont. ), an indicato r of neu ro nal inj ury • S-lOOB pro tei n (S kye Pharrna'Tech ; Mi ssissauga), an indicator of bra in injury Histologic analysis. On posteortieeetomy day 5, the monkeys were anesthetized w ith 40 mg/kg of IV sodi um pentobarbital, and the de see nding aorta was cross-clamped via a midsternal thora eot omy. A 16-gau ge ca theter was insert ed into the left cardiac ve ntrie le for perfu sion w ith 500 mi of heparinize d sa line ( 10 ID/mi ) and 500 mi of2 % paraforrnaldehyde. Th e brain and the cervical spinal cord (C I-T I) we re re moved a nd placed in a j ar co nta ining 10% bu ffered forrna lin (F isc he r Sei en tifie Co.; Fair Lawn , N.J .).
Hernatoxyl in and eosin-stained seetions were ana lyzed fo r eight histopathologic changes: ( I) the presenee or abse nce of glue at the lesion site, (2) lept omen ingeal/ cortical hernorrhage, (3) the presen ee or absence of neutrophils in the lept omeninges and at th e lesion s ite , (4) the patt ern of ede rna, (5) ca pillary proliferation and distribution , (6) astrog lial reacti on , (7) th e prese nee of macrophages, and (8) iseh emie neu ro nal c hange or neerosis in the adjacent eortex .
Stati stical analysis. The Prophet software (A bTech
Co rp.; Ch arl ott esvill e, V a.) was used for sta tistical an alysis by one-way analys is o f va ria nce (unbloc ke d) and by Tukey multiple eo mpa riso n and Student' s t tests for co mpa riso ns (sta tistical sig nifiea nee: p<0 .05).
Results
Twenty-four-hour int ensive monitoring. T hrou gh out the st udy , arterial blood press ure s and reet al te m peratures we re maintained w ithin norma l Iimi ts. All ph ysiologie variables were un remarkabl e, and the monke ys tolera ted the proeedu res wei l. Ther e was no evidenee of e pileptifo rm acti vity on EEG throug ho ut the 24 hours. Di azep am was need ed only spa ring ly ; of the 9 monkeys, 5 did not req uire any di azep arn (3 Ti sseel subjeets and 2 controis) . When diazepam was ad mi nistered. 2 Ti sseel monkeys reeeived 2 doses of 2.5 mg, I Ti sseel mon key reeeived I dose of 2.5 mg, and I eo ntrol reeeived 2.0 mg .
Five-day postsu rgical observation s. None of th e mon-
key s ex hib ited beh a vio ral signs of se izures. SS EP readings we re uneh an ged in all monkeys, a nd th ere were no sig nificant differen ees bet ween pre-an d postoperat ive ree ordings and no di ffer en ees bet ween the two gro ups (table I) . Th e only abno rrnality ob ser ved was a slig ht mon oparesis of th e right upper ex tre m ity of one of the T isseel-treated monkeys; thi s abnorma lity was prob abl y secondary to ne rve root trauma during int ratheeal Ti sseel injeetion, as suggested by a twi teh of the mo nkey's arm dur ing the injeetio n.
CSF analyses. CS F anaerobic and aerobie e ulture s (ta b le 2, top) and Gram 's sta ins were negat ive fo r bacteri a and white ee lis in all sa mples obta ined prio r to and 5 days after T isseel applicatio n, indi catin g th at the re was no infl ammatory resp on se o r infeeti on . CSF glueose and prot ein va lues pr ior to a nd 5 days fo llowing eortieee to my and lam inectomy with and wit ho ut Ti sseel application were unrem arkable. In two of the samples ob tained from mon keys in the fibrin gro up, elevated pro tein levels were clearly attributable to traum atic CSF sampling, as indica ted by bloody CSF. Findi ngs on ELISA analyses of CSF for IL-6, NSE, and S-lOOB prote in were not significantly different after the app lieat ion of T issee l in the experimental monkeys nor in the con tro is than they were beforehand (table 2, bottom).
Edema volume by T2-weiglzted M RI. Ede ma volume was assessed by de nsity threshold ing of the T2-weighted images (figure I) in the Tisseel and co ntro l monkeys (tab le 3). No significant difference in ede ma volume between the two gro ups was observed.
A DC by D WI. DWI showe d that there were no sig nifica nt differences in A DC values between the ede matous regions treated with T isseel and those that we re not trea ted .
Histopathology, Th e histologic changes observed in the regio ns of the cortieectomy with T isseel co uld be see n in the cartieal mantle and underlying subcortical white matter (figure 2). Th e area surro unding the eorticec tomy wit h Ti sseel was eharac terized by ede ma, capi llary infiltra tion, and a lack of neutrophil s ( figure 3) ; the lack of neut rophil s is impor tant because it indicates the abse nce of an infla mmatory respo nse .
Control corticec tomies exhibited a similal' degree of tiss ue necros is and perhaps sligh tly more ede ma than that obse rved with T isseel (fig ure 4, A) . The degree of eapillary proliferation and neuron al necrosis was the same (figure 4, B) .
Axia l sect ions of the C6 spinaI cord show that the Tisseel injec ted intr athecall y at C3-C4 extended down to C6 ( figure 5, A) . No tiss ue reaction was evident after histologic exa minatio n of the spina i cor d in the regions where T isseel was applied (figure 5, B ). 25 0
Discussion
Fibrin sea lants are co mmo nly used by neur osurgeons, pri mar ily to repair dural de fects , augment dural repairs, and achieve hemostasis, both intracranially and in the spi nai ca nal. Despite this widespread use and no reports of adverse effec ts from the applica tion offibrin glue directl y to the CNS ; ·27 the potential for neurotoxicit y has not been previou sly studied in nonh uman prim ates.P''<"
Th rombin , a seri ne protease enzy me, is activa ted fro m pro thro mbin by fac tors Xa and Va . 19 • 2X In its pri mary role, thrombin co nverts fibrinoge n to fibrin monomer, whic h polymerizes to for m fibri n matrix. Th rombin triggers a host of other effects on ce lls thro ugh protease-activated receptors, whieh use G pro teins to activate various cellulal' res ponses" that pro mote coag ulation, clot for matio n, cha nges in endot helial ee li shape, and endot helial permeabi lity. These responses, in turn, pro mote loeal transudation of pro teins and fluid, aetivation oflocal infla mma tory res ponses, and ge nera tion of reactive oxygen spec ies. Based on these effects, thrombin app lied direetly to or Postop ADC (10-5 cmvsec) Figure 3 . Photomicrograph of the cortical tissue shows the Tiss eel plllg (short arro\\'), the caplllary proliferation (long arrows). and the edenia in the tissue surround ing the plug.
T isseel gro up did not receive diazep am , whi le 2 rece ived only 2 doses of 2.5 mg and I rece ived I dose of 2.5 mg over the 24 hours. No ne of these mon keys exhibited any seiz ure or epileptiform acti vit y.
Perhaps more probl em atic than Ti sseeI' s poten tial effec ts on epileptiform activity, edema, or apop totic ch anges in the CN S is its potential to induce antibo dy forma tion against thrombin of ei ther bo vine or hu man or igi n.17.J 8.20.21 As both an enzy me and a protein, thrombin co uld ind uce an immune respon se by ge ne rating antibodies to itse lf and to other co mpo ne nts of the coagulatio n cascade (e.g. , fibrinogen and fac tor V), wh ich might then ca use coagul opathies. Becau se our mon keys ex pe rienced only a sing le exposure to Ti sseel , our study does not se ttle this iss ue . Ot her studies of the effects of thro mbi n in inducing ede ma, ischemi a, and antibody form ati on invol ved bovine thrombin rath er th an T isseel. Stud ies of repeated Ti sseel ex pos ures wo uld be needed to elarify th is issue.
Our ana lysis of CSF fo r IL-6, NSE , and S-l OOBpro tei n level s was co nduc ted to look for an inflammatory respo nse and neuron al da mage:
• An increase in IL-6 level is an indicator of an infla mmatory res po nse .ö" Ou r 5-day observation per iod was 84.3 ± 6.2
Preop ADC (10-5 emt/see) 130.8 ± 53.5 89.0 ± 2.5 86.5 ± 1.8
Tisseel (n =4)
Fibrin-1 Fibrin-2 Fibrin -3 into the brain might be expected to ind uce a variety of path ologic respon ses, inc luding ederna, seiz ures , and apo ptoti c changes.!' :" However, these effects have not been observed foll owing the use of T isseel in human s-and, as a result of our study , they have now bee n de mo ns trated to be abse nt in no nhuma n prima tes Control (n =3) as we Il. T he reason fo r the lack of an adverse effect fro m T issee l may be that the act of premixing thro mbi n and aprotinin (co mpo ne nt 2) with fibr inogen and fac tor XIII (compone nt 1)"9 mitigates a direet thrombin effect on the tissue."
We fo und no evi de nce of clinical seizure activi ty follow ing the app lic atio n of Ti sseel direc tly into the brain pare nchy ma . T his findi ng d iffer s fro m resul ts obtai ned by Lee et al, who injected thro mbin int o rat basal ga ng lia .!' A possible explanation for the diffe re nce bet ween their findi ngs and ours is that Lee et al injec ted pure bov ine thrombin, whereas we applied T isseel afte r prem ixin g the throm bin and apro tini n wi th fibrinogen and fac tor XIII. It is unelear whet her or no t this differen ce co uld be res po nsible for our co ntras ting findings, but the 24 hou rs of co ntinuo us EEG recordi ng pos tapplica tio n sho uld have allowed us sufficie nt tim e to deteet any seizures directl y attr ibutable to T isseel, eve n in the face of the occasional ad ministra tio n of low-d ose diazepam to so me of our study anima ls.
Th e fac t that we used d iaze pa m injected as bol us doses o f 2.0 to 2.5 mg o nce or tw ice in 4 of the 9 mon keys mig ht have masked evidence of possible se iz ure activity. Diazepam was used in so me circums tances to kee p sys tolic arte rial blood press ure beiow 140 mm Hg wi tho ut a need for excessive doses of fenta nyl, which has been impl icated in the ge ne ra tio n of se izures and bra in dam age in rats." :" However, in our study, 3 of the 6 mo nkeys in the 252 
Indieations (mild to moderate infeetions)
Acute bacterial otltl media and cute maxillary sinusitis (adults and adolescents) due to H mfluenzoe (including f3-laetamase producing strains). S pneumonioe (penicillin-susceptible strains only). and M cotarma!ls (including f3-laetamase producing strains). Use of cefdinir in the treatment of acute maxillary sinusitis in pediatnc pat.ents IS supported by evidence from adequate and well-controlled studies in adults and adolescents.
Pharyngitis/Tonsilliti due to S pyogenes. Cefdinir is effeetive in the eradication of S pyogenes from the oropharynx.
Cefdinir has not. however. been studied for the prevention of rheumatic fever following S pyogenes pharyngitis/tonsillitis, Only intramuscular penicillin has been demonstrated to be effeetive for the prevention of rheumatic fever.
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Safety information
• To reduce the development of drug-resistant baetena and rnamtain the effectiveness of OMNICEF and other antibaetenal drugs. OMNICEF should be used only to treat or prevent infeetions that are proven OI' strongly suspeeted to be caused by baetena • OMNICEF is contraindicated in patients with known allergy to the cephalosponn class of antibiotics • For patients with previous hypersensitivity reaetion to penicillins. caution should be exercised because cross-hypersensitivity among f3-laetam antibiotics has been clearly documented. If an allergic reaetion to cefdinir occurs. the drug should be discontinued • Safety and efficacy in neonates and infants lessthan 6 months have not been established • 2% of 2.289 pediatric patients discontinued medication due to adverse events in US and ex-US clinical trials. Discontinuations were primarily for gastrointestinal disturbance. usually diarrhea • The most common reported adverse events occurring in~I% of pediatric patients in US clinical trials (N= 1,783) were diarrhea (8%), rash (3%). and vomiting (I %) Referenee: I. OO ICEF' (cefdn) ior0raJ suspens.on prescrbng Pseudomembranous colilis has been reported with nearly all antibacteri alagents, includi ngceldinir, and may range inseverityIrom mild-to lile-thr eatening. Therelore , it is important to consider thi s diagnosis in patients who present with diarrhea subsequent to the administration01 antibacterlal agents. Treatment withantibaeterial agents alters thenormalIlora 01 the eolonand may permit ove rg r ov~h 01 elostridia. St udi es indieate that a toxin produeed by Clostridium ddlieile is a prima ry eause 01 "ant ibiotieassociated eolitis. "
. Al terthe di agnosi s 01pseudomembranous eolitis has been established, appropriate therapeutie measures should be initialed. Mild cases 01 pseudomembranous eolitis usuall y respond to drug diseontinuat ion alone. In moder ate to severe cases, eonsideration should be given to management with f1uids and eleetrolytes. protein supplementation. and Ireat menlwi thanantibaeterial drugelinieall y effeetive againstClostridium dillieile. PRECAUTIDNS General Preseribing OMNICEf in the absenee 01a proven or strongly suspeeted baeteria l inleeti on oraprophylaetieindi eationisunlikelytoprovide benefit tothepatient andincreasesthe risk 01 thedevel opment 01drug-resi stant baeteria. As witholher broad -speetrumantibioties, prolonged treatment may result inthepossi bleemergenee and ove rg rOl 'h 01resistant organisms. Carelul observation 01the patient is essential. II superinleetion oeeurs during therapy. approp riatealtemative therapy should beadministered. Celdinir . aswith olherbroad-speetrum antimierobials(antibioties). should bepreseribed with eautioninindividualswithahi story01 eolitis. In patients with transi ent or persistent renal insuffiei eney (ereatini ne elearanee <3D mUmin), the total daily dose 01 OMNICEf shouId be redueed beeause hi gh and prol onged plasma eoneentrations 01eeldinir eanresult loll owing reeommendeddoses. Inlormation lor Patienls Patients shoul d be eounseledthat antibaeterial drugsineludingOMNICEF should only be used to treat baet erialinleetions. They do not treat viral inleetions (e.g" the common cold).When OMNI CEf is preseribed totreat abaeterial inleetion. patients shouldbe toldIhatallhoughit iscommonto leel bett erearly in theeourse 01 therapy. themedieation shouIdbe taken exaelly as directed. Skipping doses or not eomplet ingthe lulleourse ot therapy may (1) deerease the elleetiveness 01the immedi atetreatment an d (2) inerease the likelihood that baeteria will develop resistanee and wi ll not betreatable byOMNICEf or other anti baeterial drugsintheluture. Antaeids containi ng magnesiu m or aluminum interlere with the absorption 01eeldinir.II this type 01 antacidis required during OMNICEf therapy . OMNICEF should be taken at least 2 hours beloreor alter the antaeid. lron supplements, inel udingmultivitaminsthat eontainiron. interlerewith the absorption 01 eeldinir. II iron supplements are required during OMNICEF ther apy. OMNICE f should be taken at least 2 hours beloreor alter thesupplemenl. Iron-Iort ilied inlant lormula does not signilieantly intertere wi th the absorption 01 cel di nir.Therelore, OMNICEf lor Oral Suspension ean be administered wit h iron-lortilied inlant lormula. Diabetiepatientsandearegivers shouldbe awarethat the oral suspension eontains 2.86 9 01suerose per teaspoon, Drug Interaetions Antaeids: laluminum-or magnesium-eontaining): Coneomitant administration 01 300-mg eeldinir eapsules with30 mL Maa l ox~TCsuspe nsion reduees the rate (Cm ,,) and ex1ent (AUC) 01absorption byapproximately 40%. Ti me 10 reaeh Cm " is also prolonged by 1 hour. There are no signilieant effeets on eeldinir pharmaeokineti es il the antacid is administered 2 hours belore or 2 hours alter eeldinir. II antaeids are required during OMNICEf the rapy. OMNICEf should be taken at least 2 hours beloreoralter the antaeid. Probenecid: As with other p-Iaetam antibioties. probeneeid inhibi ts the renal exeretion 01 celdinir. resulting inanapproximate doubli ng inAUC. a 54% inerease in peak eeldinirpl asma levels. and a50% prolongation in the apparent elimination II" . Iron Supplements and Foods Forlilied With Iron: Coneomitant adminis trat ion 01 eeldini r with a therape ut ieiron supplement containing 60mg 01 elementat iron (as feSO,) orvitamins supplemented with 10 mg 01 elemental iron redneed extent 01 absorption by 80% and 31 %. respeetively. II iron supplements are required during OMNICEf therapy. OMNICEf should be takenatleast 2 hoursbelore oralter the supplemenl. The enect 01 loods hi ghly lortilied wit h etemental iron (primarily ironlortilied break last cereals) on eeldinir absorption has not been studied. Coneomitanlly administered iron-Iortilied inlanl lormula (2.2 mg elemental ironJ6 oz) has no signilieant effeet on eeldini r pharmaeokineties. Theretere. OMNICEf lor Oral Suspension ean be administered with iron-Iortilied inlant lormula. I here havebeenreports01 reddishsteots inpatientsreeeivingeeldinir.In manycases. patients werealso reeeiving iron-eonlaining produets. The reddi shcolorisdue tothe lormation 01 anonabsorbabl eeomplex between eeldinir or ltsbreakdown produetsandiron inthe gastrointestinal trael. Drug/laboratory Tesllnteraclions . A Ialse-positive reaetion lor ketones in the urinemay oeeur wit h tests using nitrop russide, but not wit h those using nit rolerrieyanide. The administrat ion 01 eeldini r may result in a talse-posifive reaetion lor glueose in urine using Cl i ni t est~. Benediet' s solution, or fehling 's sol ution. It is reeommended that glueose tests based on enzymatie gl ueose oxidase reaetions (such as Clinistix 3 or T es -T ap e~) be used. Cephalosporins are known to oeeasionally induee a posltive di reet Coombs' test. Carcinog enesis, Mutagenesis. Impairment ofFertility The eareinogenie potential 01 eeldini r has not been evaluated. No mutagenie effeets were seen in the baeterial reverse mutation assay (Ames) or point mu tation assay at the hypoxanthi ne-guanine phosphoribosyltranslerase 10GUS (HGPRT) in V79 Chinese hamster lung eelis. No elastooene eüeets were observed in vitro in the struetural ehromosome aberration assay in V79 Chinese hamsterlung eelis or in vivo in the mieronueleus assay in mouse bone marrow In rats, lert ility and reproductiveperlormaneewerenot affeeted by eeldini r atoral doses upto 1000mglkg/day (70times the human dosebased onmg/kg/day. 11 times based onmg/m'/day) . Pregnancy -Teratogenie Elleets Pregnancy Category B: Celdinir was not teratogenie inrats atoral doses upto 1000mg/kg/day (70times the human dosebasedon mglkg/day. 11 times basedonmg/m'/day) or inrabbi tsatoraldoses upto10mglkg/day (0.7 times thehuman dose based on mglkg/day, 0.23 times based on mg/m' /day). Materna i toxieity (deerease d body weight gain) was observed in rabbits at the max imum toleratee dose 01 10 mglkg/day without adverse effeets on offspringoDeereased body weight oeeurred in rat letuses at~1 0 0 mg/kg/day. and inrat offspringat~32 mglkg/day. No et teets wereobserved on maternai reproductive parameters or offspring survival, development. tehavior, or reproductivelunetion. Thereare. however . noadequate and well-eontro lled studies in preg nant women. Beeauseani mal reproductionstud ies arenot always predietive 01 human response, this drug should be used during pregna ney only il elearlyneeded. Labor and Delivery Celdinir has notbeen studiedloruseduringlabor anddelivery. Nursing Mothers Following administration 01 single 600-mg doses, eeldinir \'Ias not deteeted in human breastmilk. Pedialrle Use Salety andeffieaey inneonates andinlantslessthan6months01 age have not been established. Use 01 eeldini r lor thetreatment 01aeute maxillary sinusilis in pediatrie patients (age 6 months through 12 years) is supported by evidenee Irom adequate and well-eontrolled studies in aduits and adoleseents. the similar pathophysiology 01aeute sinusitis in adult and pedi atriepatients, andeomparative pharmaeokinetiedatainthe pediatriepopul ation. Geriatric Use Effi eaey is eomparab le in geriatrie pati ents and younger adulis. While eeldinir has been well-tolerated inall age groups. inelinieal trial sgeriatrie patients experieneed a lower rat e 01adverse events. inel udi ngdiarrhea. than you nger aduits. Doseadjustment inelderlypatientsisnotneeessary uniess renallunetion is markedly eomprom ised. ADVERSE EVENTS ClinicalTrials-OMNICEF Cap sules (Adult and Adole scent Patients): In elinieal trial s. 5093 adult and adoleseent patie nts (3841 USand 1252 non-US) were treat ed with the reeommended dose 01eeldini r eapsules (600 mg/day). Most adverse events weremil dan dsell-limit ing. No deaths or permanent disabilities wereattr ibuted to celdinir.One hundred lortyseven 01 5093 (3%) patients di seontinued medieation due to adverse events thought bytheinvestigat ors to be possibly. probably. or delinitely associated with eeldi nir ther apy. Thediseontinuations were primarilyfor gastrointestinal disturbanees, usually di arrhea or nausea. Ni neteen 01 5093 (0.4%) patients were diseontinued due to rashthought rel at ed to eeldinir administration. In the US. thelollowingadverse eventswerethought byinvestigators to be possibl y. probably. ordel initelyrelatedtoeeldinir eapsules inmul tipl edoseelinieal trials IN: 384 1eeldinir-treated patients): ADVERSEEVE NTSASSOCIA TEDWITHCEfDlNIR CAPSULESUSTRIALSIN ADULT AND ADOLESCENT PATlENTS (N:3841)': Incidenee~1 % . Di arrhea15%. Vaginal moniliasis 4%01\'lomen. Nausea 3%. Headaehe 2%. Abdominal pain 1%, Vaginitis 1% 01 women, Incidenee <1% but >0.1%, Rash 0.9%, Dyspepsia 0.7%. Hatulenee 0.7%. Vomi ting 0.7%. Abno rmal stools 0,3%, Ano rexia 0.3%, Constipation 0.3%. Dizziness 0.3%. Dry mouth 0.3%. Asthenia 0.2%, Insomnia 0.2%, Leukorrhea 0.2% 01 women, Moniliasis 0.2%. Prur itus 0.2%, Somnolenee 0.2%, ' 1733 males. 2108lemales. Theloll owing laboratoryvaluechan ges 01 possibl eelinieal signitieanee, irrespeetive 01 rel ationship to therapy with cel dinir , were seen during elinieal trials eondueted in the US: LASORATORY VALUE CHANG ES OBSERVED WITH CEfDlNIR CAPSULES US TRIALS IN ADULT AND ADOLESCENT PATIENTS (N:3841): Incidenee~1 % ,i Urine leukoeytes 2%, i Urine protein 2%, i Gamma-tg lutamyltranslerasea 1%, t Lymphoeytes, i Lymphoeytes 1%. 0.2%, iMierohematu ria 1%. Incidenee <1% but >0.1% i Glueose' 0.9%, i Urine glueose 0.9%, i White blood eelis. t White blood eeli s 0.9%, 0.7% iA lanlne aminot ranslerase (ALT) 0.7%, i Eosinophi ls 0.7%. suffieiently lon g to enable us to observe any increases in IL-6 had ther e been any .
• NSE-a 78-kDa protein that orig inates primaril y in neur ons and neur oend oerine ee lls-shou ld be a sensitive marker for neur onal degradation." Inereased CSF levels of NSE have been found in dogs and rats subjeeted to ear diae arres t,2I.29 Creut zfeldt-lakob disease," head inj ury,40AI and foea l ischernia."
• S-lOOB protein-an aeidie ealeium-binding protein that is present in high eoneentrations in glial and Seh wann ' s eelis-is relea sed into serum and CSF afte r CN S eeli degrad ation . It has been shown to be an indieator of CNS damage afte r eardiae surgery. "
Neith er IL-6 , NSE, nor S-lOOB protein levels were eleva ted in the CSF samples we drew before and after eor tieee tomy and applieat ion of Tisseel to the brain. Th ese findings coneur wit h our histopathologie obser vations. Aeeording to these findings , Tisseel does not appear to induee any more tissue inflammation, ede ma, or isehemi e injury than does eor tieeetomy alone.
In eo ncl usion, the results of our study show that T isseel eau ses no adverse effeets when it is plaeed direetly into Volume 83, Number 4 the brain and onto the spinal cor d of nonhuman prim ates. Based on ou r findings, we eoncl ude that Ti ssee l is beni gn with respeet to aeute interactions with the human brain and spinal cord.
